(Co. Reg. No: 200405621W)

NEWS RELEASE

iX BIOPHARMA ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ERECTILE DYSFUNCTION DRUG

- ✓ **Results of pivotal study confirm bioequivalence and good oral tolerability of sublingual sildenafil wafer (PheoniX) when compared with reference drug**

Singapore, 13 September 2016 – Homegrown specialty pharmaceutical company **iX Biopharma Ltd.** ("iX Biopharma" or, together with its subsidiaries, "the Group") is pleased to announce the positive results of a pivotal bioequivalence study comparing iX Biopharma's novel sildenafil wafer (**PheoniX**) with the reference drug (in this instance the oral tablet, Viagra®). Sildenafil is the active compound in both **PheoniX** and the reference drug and is used in the treatment of male erectile dysfunction.

The study compared the pharmacokinetics (i.e., absorption, distribution, metabolism and elimination) of sildenafil between **PheoniX** and the reference drug. The study achieved its primary objective by demonstrating that the sublingual wafer formulation of **PheoniX** had a similar rate and extent of drug absorption as the reference drug. **PheoniX** was well-tolerated and there were no serious adverse events reported.

Dr Janakan Krishnarajah, Chief Medical Officer said, "We are very pleased that the study demonstrated bioequivalence between **PheoniX** and the reference drug. We are excited to reach this important milestone for **PheoniX** which brings iX Biopharma closer to delivering our novel **WaferiX** technology to the market. On the back of this positive results, the Group will proceed to apply for registration of **PheoniX** with the Therapeutic Goods Administration (TGA) in Australia."

PheoniX is Halal-certified and one of several other drugs in iX Biopharma's product pipeline. Other products under development include **Wafermine** and **BnoX** for pain management, and **WafeRest** for improved sleep quality.

About iX Biopharma Ltd

iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, with manufacturing and laboratory testing facilities in Australia. The Group is focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health issues. The Company leverages its patented sublingual drug delivery technology, **WaferiX**, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by the United States Food and Drug Administration. Its pipeline of products under development includes **Wafermine** and **BnoX** for pain management, **PheoniX** for erectile dysfunction, and **WafeRest** for improved sleep quality.

Contact for media:

Ms Alvina Tan
DID: +65 6221 2123
H/P: +65 9787 7267
Email: alvina.tan@arkadvisors.com.sg

Ms Karin Lai
DID: +65 6221 0081
H/P: +65 9837 8136
Email: karin.lai@arkadvisors.com.sg

This document has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, CIMB Bank Berhad, Singapore Branch, for compliance with the relevant rules of the SGX-ST. CIMB Bank Berhad, Singapore Branch, has not independently verified the contents of this announcement. This document has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr Tony Toh, Director, Investment Banking, CIMB Bank Berhad, Singapore Branch. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, telephone: (65) 6337-5115.